High prevalence of p16 genetic alterations in head and neck tumours

British Journal of Cancer

Volumn 81, Issue 4, 1999, Pages 677-683

  Miracca, E C ^a   Kowalski, L P ^b   Nagai, M A ^a  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

^b A C CAMARGO CANCER CENTER   (Brazil)

Author keywords

Head and neck tumours; Hypermethylation; LOH; p16

Indexed keywords

DNA; MICROSATELLITE DNA; PROTEIN P16;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CPG ISLAND; DNA SEQUENCE; EXON; FEMALE; GENE INACTIVATION; GENE MUTATION; HEAD AND NECK CARCINOMA; HETEROZYGOSITY LOSS; HUMAN; HUMAN TISSUE; MALE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; SINGLE STRAND CONFORMATION POLYMORPHISM; SOUTHERN BLOTTING; SQUAMOUS CELL CARCINOMA;

ADULT; AGED; AGED, 80 AND OVER; DNA METHYLATION; FEMALE; GENES, P16; HEAD AND NECK NEOPLASMS; HUMANS; LOSS OF HETEROZYGOSITY; MALE; MIDDLE AGED; MUTATION;

EID: 0032886780     PISSN: 00070920     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bjc.6690747     Document Type: Article

References (54)

1. Arap W, Knudsen E, Sewell DA, Sidransky D, Wang JY, Huang HJ and Cavenec WK (1997) Functional analysis of wild type and malignant glioma derived CDKN2Abeta alleles: evidence for an Rb-independent growth supressive pathway. Oncogene 15: 2013-2020
2. Cairns P, Mao L, Merlo A, Lee DJ, Schwab D, Eby Y, Tokino K, van der Riet P, Blaugrund JE and Sidransky D (1994) Rates of p16 (MTS1) mutations in primary tumors with 9p loss. Science 265: 415-416
3. Cairns P, Polascik TJ, Eby Y, Tokino K, Califano J, Merlo A, Mao L, Herath J, Jenkins R, Westra W, Rutter JL, Buckler A, Gabrielson E, Tockman M, Cho KR, Hedrick L, Bova GS, Isaacs W, Koch W, Schwab D and Sidransky D (1995) Frequency of homozygous deletion at p16/CDKN2 in primary human tumours. Nat Genet 11: 210-212
4. Caldas C, Hahn SA, Costa LT, Redston MS, Schutte M, Seymour AB, Weinstein CL, Hruban RH, Yeo CJ and Kern SE (1994) Frequent somatic mutations and homozygous deletions of the p16 (MTS1) gene in pancreatic adenocarcinoma. Nat Genet 8: 27-32
5. Califano J, van der Riet P, Westra W, Nawroz H, Clayman G, Piantadosi S, Corio R, Lee D, Greenberg B, Koch W and Sidransky D (1996) Genetic progression model for head and neck cancer: implications for field cancerization. Cancer Res 56: 2488-2492
6. Chin L, Pomerantz J and DePinho RA (1998) The INK4a/ARF tumor supressor: one gene, two products, two pathways. Trends Biochem. Sci 23: 291-296
7. El-Naggar AK, Lai S, Clayman G, Lee JK, Luna MA, Goepfert H and Batsakis JG (1997) Methylation, a major mechanism of p16/cdkn2 gene inactivation in head and neck squamous carcinoma. Am J Pathol 151: 1767-1774
8. Farrell WE, Simpson DJ, Bicknell JE, Talbot AJ, Bates AS and Clayton RN (1997) Chromosome 9p deletions in invasive and noninvasive non-functional pituitary adenomas: the deleted region involves markers outside of the MTS1 and MTS2 genes. Cancer Res 57: 2703-2709
9. INK4b genes, as well as neighboring 9p21 markers, in sporadic melanoma. Cancer Res 56: 5023-5032
10. Fucyo J, Gomez Manzano C, Bruner JM, Saito Y, Zhang B, Zhang W, Levin VA, Yung WA and Kyritsis AP (1996) Hypermethylation of the CpG island of p16/cdkn2 correlates with gene inactivation in gliomas. Oncogene 13: 1615-1619
11. Furlong RA, Lyall JE, Lush MJ, Affara NA and Ferguson-Smith MA (1992) Four dinucleotide repeat polymorphisms on chromosome 9(D9S143-D9S146). Hum Mol Genet 1: 447
12. Gallo O, Santucci M and Franchi A (1997) Cumulative prognostic value of p16/cdkn2 and p53 oncoprotein expression in premalignant laryngeal lesions. J Natl Cancer Inst 89: 1161-1163
13. Gonzáles MV, Pello ME, López-Larrea C, Suárez C, Menéndez MJ and Coto E (1997) Deletion and methylation of the tumour supressor gene p16/cdkn2 in primary head and neck squamous cell carcinoma. J Clin Pathol 50: 509-512
14. Gyapay G, Morissete J, Vignal A, Dib C, Fizames C, Millasseau P, Marc S, Bernardi G, Lanttrop M and Weissenbach J (1994) The 1993-1994 généthon human genetic linkage map. Nat Genet 7: 246-339
15. Herman JG, Merlo A, Mao L, Lapidus RG, Issa JPJ, Davidson NE, Sidransky D and Baylin SB (1995) Inactivation of the cdkn2/p16/MTS1 gene is frequently associated with aberrant DNA methylation in all common human cancers. Cancer Res 55: 4525-4530
16. Hunter T and Pines J (1994) Cyclins and cancer II: cyclin D and CDK inhibitors come of age. Cell 79: 573-582
17. Hussussian CJ, Struewing JP, Goldstein AM, Higgins PAT, Ally DS, Sheahan MD, Clark WH, Tucker MA and Dracopoli NC (1994) Germline p16 mutations in familial melanoma. Nat Genet 8: 15-21
18. MTS1/CDK41 mutations and concomitant loss of heterozygosity at 9p21-23 are frequent events in squamous cell carcinoma of the larynx. Oncogene 15: 1445-1453
19. Jarrard DF, Bova GS, Ewing CM, Pin SS, Nguyen SH, Baylin SB, Cairns P, Sidransky D, Herman JG and Isaacs WB (1997) Deletional, mutational and methylation analyses of CDKN2 (p16/MST1) in primary and metastatic prostate cancer. Genes Chromosomes Cancer 19: 90-96
20. Kamb A, Gruis NA, Weaver-Feldhaus J, Liu Q, Harshman K, Tavtigian SV, Stockert E, Day III RS, Johnson BE and Skolnick MH (1994a). A cell cycle regulator potentially involved in genesis of many tumor types. Science 264: 436-440
21. Kamb A, Shattuck-Eidens D, Eeles R, Liu Q, Gruis NA, Ding W, Hussey C, Tran T, Miki Y, Weaver-Feldhaus J, McClure M, Aitken JF, Anderson DE, Bergman W, Frants R, Goldgar DE, Green A, MacLennan R, Martin NG, Meyer LJ, Youl P, Zone JJ, Skolníck MH and Cannon Albríght LA (1994b). Analysís of the p16 gene (CDKN2) as a candidate for the chromosome 9p melanoma susceptibility locus. Nat Genet 8: 22-26
22. Kamijo T, Weber JD, Zambetti G, Zindy F, Roussel MF, Sherr CJ (1998) Functional and physical interactions of the ARF tumor supressor with p53 and Mdm2. Proc Natl Acad Sci USA 95: 8292-8297
23. Kaplan EL and Meier P (1958) Non-parametric estimation from incomplete observations. J Am Stat Assoc 53: 457-481
24. Kim SK, Ro JY, Kemp BL, Lee JS, Kwon TJ, Fong KM, Sekido Y, Minna JD, Hong WK and Mao L (1997) Identification of three distinct tumor suppressor loci on the short arm of chromosome 9 in small cell lung cancer. Cancer Res 57: 400-403
25. Koh J, Enders GH, Dynlacht BD and Harlow E (1995) Tumor-derived p16 alleles encoding proteins defective in cell-cycle inhibition. Nature 375: 506-510
26. Kwiatkowski DJ and Diaz MO (1993) Dinucleotide repeat polymorphism at IFNA locus (9p22). Hum Mol Genet 1: 658
27. Liggett WH Jr, Sewell DA, Rocco J, Ahrendt SA, Koch W and Sidransky D (1996) p16 and p16β are potent growth suppressors of head and neck squamous carcinoma cells in vitro. Cancer Res 56: 4119-4123
28. Lo KW, Cheung ST, Leung SF, van Hasselt A, Tsang YS, Mak KF, Shung YF, Woo JKS, Lee JCK and Huang DP (1996) Hypermethylation of p16 gene in nasopharyngeal carcinoma. Cancer Res 56: 2721-2725
29. Lydiatt WM, Murty VVVS, Davidson BJ, Xu L, Dyomina K, Sacks PG, Schantz SP and Chaganti RSK (1995) Homozygous deletions and loss of expression of the CDKN2 gene occur frequently in head and neck squamous cell carcinoma cell lines but infrequently in primary tumors. Genes Chrom & Cancer 13: 94-98
30. Maesawa C, Tamura G, Nishizuka S, Ogasawara S, Ishida K, Terashima M, Sakata K, Sato N, Saito K and Satodate R (1996) Inactivation of the CDKN2 gene by homozygous deletion and de Novo methylation is associated with advanced stage esophageal squamous cell carcinoma. Cancer Res 56: 3875-3878
31. Merlo A, Herman JG, Mao L, Lee DJ, Gabrielson E, Burger PC, Baylin SB and Sidransky D (1995) 5′CpG island methylation is associated with transcriptional silencing of the tumor suppressor p16/CDKN2/MTS1 in human cancers. Nat Med 1: 686-692
32. Mori T, Miura K, Aoki T, Nishihira T, Mori S and Nakamura Y (1994) Frequent somatic mutation of MTS1/CDKN4I (multiple tumor suppressor/cyclin dependent kinase 4 inhibitor) gene in esophageal squamous cell carcinoma. Cancer Res 54: 3396-3397
33. Nagai MA, Marques LA, Torloni H and Brentani MM (1993) Genetic alterations in c-erbB-2 protooncogene as prognostic markers in human primary breast tumors. Oncology 50: 412-417
34. Nawroz H, van der Riet P, Hruban RH, Koch W, Ruppert JM and Sidransky D (1994) Allelotype of head and neck squamous cell carcinoma. Cancer Res 54: 1152-1155
35. Ng MHL, Chung YF, Lo KW, Wickham NWR, Lee JCK and Huang DP (1997) Frequent hypermethylation of p16 and p15 genes in multiple myeloma. Blood 89: 2500-2506
36. Nobori T, Miura K, Wu DJ, Lois A, Takabayashi K and Carson DA (1994) Deletions of the cyclin-dependent kinase 4 inhibitor gene in multiple human cancers. Nature 368: 753-756
37. Okamoto A, Demetrick DJ, Spillare EA, Hagiwara K, Hussain SP, Bennett WP, Forrester K, Gerwin B, Serrano M, Beach DH and Harris CC (1994) Mutations and altered expression of p16 in human cancer. Proc Natl Acad Sci USA 91: 11045-11049
38. INK4a in oral premalignant lesions. Oncogene 14: 1799-1803
39. Pollock PM, Pearson JV and Hayward NK (1996) Compilation of somatic mutations of the CDKN2 gene in human cancers: non random distribution of base substitutions. Genes Chromosomes Cancer 15: 77-88
40. Puig S, Ruiz A, Lázaro C, Castel T, Lynch M, Palou J, Vilalta A, Weissenbach J, Mascaro JM and Estivill X (1995) Chromosome 9p deletions in culaneous malignant melanoma tumors: the minimal deleted region involves markers outside de p16 (CDKN2) gene. Am J Hum Genet 57: 395-402
41. ARF. Proc Natl Acad Sci USA 94: 669-673
42. Quelle DE, Zindy F, Ashmun RA and Sherr CJ (1995) Alternative reading frames of the INK4a tumor supressor gene encode two unrelated proteins capable of inducing cell cycle arrest. Cell 83: 993-1000
43. Ranade K, Hussussian CJ, Sikorski RS, Varmus HE, Goldstein AM, Tucker MA, Serrano M, Hannon GJ. Beach D and Dracopoli NC (1995) Mutations associated with familial melanoma impair p16 (INK4) function. Nat Genet 10: 114-116
44. Reed AL, Califano J, Cairns P, Westra WH, Jones RM, Koch W, Ahrendt S, Eby Y, Sewell D, Nawroz H, Bartek J and Sidransky D (1996) High frequency of p16 (CDKN2/MTS-1/INK4A) inactivation in head and neck squamous cell carcinoma. Cancer Res 56: 3630-3633
45. Serrano M, Hannon GJ and Beach D (1993) A new regulatory motif in cell cycle control causing specific inhibition of cyclin D/CDK4. Nature 366: 704-707
46. Serrano M, Lee H, Chin L, Cordon Cardo C, Beach D, DePinho RA (1996) Role of INK4a locus in tumor supression and cell mortality. Cell 85: 27-37
47. Stone S, Jiang P, Dayananth P, Tavtigian SW, Katcher H, Parry D, Peters G and Kamb A (1995) Complex structure and regulation of the p16 (MTS1) locus. Cancer Res 55: 2988-2994
48. Sun Y, Hildesheim A, Lanier AE, Cao Y, Yao KT, Raab-Traub N and Yang CS (1995) No point mutation but decreased expression of p16/MTS1 tumor suppressor gene in nasopharyngeal carcinomas. Oncogene 10: 785-788
49. INK4. Cancer Res 54: 5816-5820
50. van der Reit P, Nawroz H, Hruban RH, Corio R, Tokino K, Koch W and Sidransky D (1994) Frequent loss of chromosome 9p21-22 early in head and neck progression. Cancer Res 54: 1156-1158
51. Williamson MP, Elder PA, Shaw ME, Devlin J and Knowles MA (1995) p16 (CDKN2) is a major deletion target at 9p21 in bladder cancer. Hum Mol Genet 4: 1569-1577
52. Wong DJ, Barret MT, Stöger R, Emond MJ and Reid BJ (1997) p16INK4a promoter is hypermethylated at high frequency in esophageal adenocarcinomas. Cancer Res 57: 2619-2622
53. Yeundall WA and Jakus J (1995). Cyclin kinase inhibitors add a new dimension to cell cycle control. Eur J Cancer B Oral Oncol 31B: 291-298
54. Zhang SY, Klein-Szanto AJP, Sauter ER, Shafarenko M, Mitsunaga S, Nobori T, Carson DA, Ridge JA and Goodrow TL (1994) Higher frequency of alterations in the p16/CDKN2 gene in squamous cell carcinoma cell lines than in primary tumours of the head and neck. Cancer Res 54: 5050-5053